New IgE antibody trial targets Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific marker (folate receptor alpha). The study has two parts: first, finding a safe dose, and then checking how well the drug w…
Phase: PHASE1 • Sponsor: Epsilogen Ltd • Aim: Disease control
Last updated Apr 29, 2026 00:36 UTC